While the mechanisms determining p110 isoform dominance in PTEN-deficient prostate cancer remain unknown, this finding has important clinical implications that loss of PTEN alone will not be a biomarker of p110β inhibition sensitivity. The gene discussed is PTEN; the disease is prostate carcinoma.